Adjuvant Hormonal Therapy for Stage I Endometrial Cancer
Author Information
Author(s): Lilian Gien, J. Kwon, T.K. Oliver, M. Fung-Kee-Fung
Primary Institution: Cancer Care Ontario
Hypothesis
What is the role of hormonal therapy as adjuvant therapy in patients with stage I endometrial cancer?
Conclusion
The evidence does not support the use of adjuvant hormonal therapy for patients with stage I endometrial cancer.
Supporting Evidence
- Nine randomized trials and one meta-analysis were reviewed.
- One trial showed a statistically significant survival benefit with adjuvant progestogen.
- Two trials reported statistically significant recurrence-free benefits.
- Overall, eight of the nine trials found no significant difference in survival.
Takeaway
Doctors looked at studies to see if hormonal therapy helps women with early-stage endometrial cancer after surgery, but they found it doesn't really help.
Methodology
A systematic review of randomized controlled trials, practice guidelines, systematic reviews, and meta-analyses was conducted.
Potential Biases
Differences in baseline characteristics between treatment groups may have influenced outcomes.
Limitations
The trials had inconsistent reporting, lacked quality of life data, and included patients with varying stages of cancer.
Participant Demographics
Women with newly diagnosed stage I endometrial cancer.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% ci: 0.88 to 1.24
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website